CELLANTRATECH THERAPEUTICS
In vivo gene therapy. Precision oncology.
A preclinical in vivo gene-therapy biotechnology company advancing two lead targeted mRNA-LNP medicines, intracellular KRAS payloads and in vivo engineered-TCR programs.
ABOUT CELLANTRATECH THERAPEUTICS
A Preclinical In Vivo Gene-Therapy Biotechnology Company
CellentraTech is advancing two targeted mRNA-LNP co-lead programs supported by a reusable in vivo delivery platform and a focused pipeline of engineered-TCR and gene-editing programs
“The product is the integrated system — not the ligand, payload or carrier in isolation.”
OUR DEVELOPMENT APPROACH
A common validation system makes portfolio decisions comparable
01.
Access
Confirm target binding or intended cell-type recognition, specificity, and accessibility in the relevant disease compartment.
02.
Delivery & Expression
Demonstrate target-dependent uptake or transduction, payload integrity and expression, with reproducibility across relevant conditions.
03.
Function & Safety
Establish disease-relevant function while assessing cross-reactivity, off-target activity, tissue safety, and independent confirmation.
04.
Reproducibility
Require reproducible performance across relevant conditions, supported by appropriate controls, comparators, and independent confirmation.
05.
Product Quality
Build identity, integrity, consistency, stability and fit-for-purpose analytical controls into development from the start.
06.
Decision Discipline
Advance programs only when integrated evidence supports the next stage; redesign, add controls, or stop when results are negative or ambiguous.
OUR PLATFORM
A Reusable Nonviral Delivery Platform
CellentraTech is a preclinical biotechnology company building a reusable nonviral delivery platform and two co-lead oncology programs.
Two Co-Lead Programs
A20T013/W2993 and G059 are evaluated under the same preclinical development framework.
Reusable Platform
Shared delivery and development capabilities are intended to improve learning across programs.
Milestone Discipline
Independent evidence gates support focused capital allocation as uncertainty is reduced.
Early Product Focus
Safety, analytics, and product quality are incorporated before late-stage spending decisions.
CURRENT PRIORITIES
Milestone-Driven Value Creation
Near-term work is designed to reduce the major biological, delivery, product-quality, and safety uncertainties before any development-candidate decision or major increase in program investment.
Advance both co-lead programs through controlled preclinical evidence gates. Strengthen reproducibility across scientific rationale, delivery, function, and safety. Establish product-quality and analytical controls appropriate for the development stage.
